8 maggio 2024 – On 2 May, SOPHiA GENETICS SA (NASDQ: SOPH), a Swiss data-driven medicine software company, closed a secured term loan financing for up USD 50,000,000 from funds managed by Perceptive Advisors, LLC, a privately owned hedge fund sponsor that invests in biotechnology and life sciences sectors in public equity markets across the globe.

Walder Wyss advised the funds managed by Perceptive Advisors, LLC. The team was led by Tervel Stoyanov (Counsel, Banking & Finance) and further included Urs P. Gnos (Partner, Corporate / M&A), Iliana Djagova (Counsel, Corporate / M&A) and Maurus Winzap (Partner, Tax).